Compare NMIH & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMIH | ICUI |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 2013 | 1995 |
| Metric | NMIH | ICUI |
|---|---|---|
| Price | $38.92 | $125.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $43.25 | ★ $169.00 |
| AVG Volume (30 Days) | ★ 438.4K | 210.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 100.62 |
| EPS | ★ 1.28 | 1.20 |
| Revenue | $706,440,000.00 | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | $4.46 |
| P/E Ratio | ★ $30.13 | $4,118.83 |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $34.84 | $107.02 |
| 52 Week High | $43.20 | $160.29 |
| Indicator | NMIH | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 52.97 |
| Support Level | $38.52 | $121.52 |
| Resistance Level | $40.14 | $133.16 |
| Average True Range (ATR) | 1.14 | 4.54 |
| MACD | -0.24 | 0.51 |
| Stochastic Oscillator | 48.21 | 68.23 |
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.